Vardenafil Dosage

Istradefylline 40 mg/day increased peak levels and AUC of CYP3A4 substrates in clinical trials.

This effect was not observed with istradefylline 20 mg/day.

• Vardenafil 5 mg is a PDE5 inhibitor for erectile dysfunction.
• It helps men achieve and maintain an erection suitable for intercourse.
• Vardenafil 5 mg is often prescribed when other treatments fail.
• This medication can be taken with or without food.
• The effects of Vardenafil 5 mg last about 4-6 hours.
• It is important to follow your healthcare provider’s instructions.
• Avoid high-fat meals close to taking Vardenafil for faster effect.
• Combining Vardenafil 5 mg with recreational drugs is dangerous.
• It may interact with blood pressure medications.
• Do not exceed the prescribed dose to prevent risks.
• Vardenafil 5 mg is generally well-tolerated.
• Always check for contraindications before use.

Consider dose reduction of sensitive CYP3A4 substrates.

How to Order

haloperidolhaloperidol and vardenafil both increase QTc interval. haloperidol and vardenafil both increase QTc interval. hydrocortisonehydrocortisone will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. hydrocortisone will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. hydroxyzinehydroxyzine and tadalis oral jelly vardenafil both increase QTc interval.

Visual disturbances

hydroxyzine and vardenafil both increase QTc interval. ibrexafungerpibrexafungerp will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors imatinibimatinib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors imatinib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors Drugs that are known to prolong the QTc interval may have an increased the risk of ventricular arrhythmias. istradefylline will increase the level or effect

of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Other Comments

fludrocortisone will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. fluvoxaminefluvoxamine will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors fluvoxamine will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors fosamprenavirfosamprenavir will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors fosamprenavir will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Usual Adult Dose for:

Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors fosaprepitantfosaprepitant will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors fosaprepitant will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be super p force online reduced if coadministered with moderate or strong CYP3A4 inhibitors fosfomycinfosfomycin and vardenafil both increase QTc interval. The risk of QT prolongation may increase in patients with electrolyte abnormalities (such as hypokalemia and hypocalcemia), patients with conditions that have potential to cause electrolyte imbalance (such as renal impairment), or patients taking other drugs affecting electrolyte balance or QT prolongation; avoid this drug in patients with known QT prolongation or ventricular arrhythmias, including a history of torsade de pointes; monitor electrolytes during treatment fosfomycin and vardenafil both increase QTc interval. The risk of QT prolongation may increase in patients with electrolyte abnormalities (such as hypokalemia and hypocalcemia), patients with conditions that have potential to cause electrolyte imbalance (such as renal impairment), or patients taking other drugs affecting electrolyte balance or QT prolongation; avoid this drug in patients with known QT prolongation or ventricular arrhythmias, including a history of torsade de pointes; monitor electrolytes during treatment fosphenytoinfosphenytoin will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Semantic Clinical Drug (SCD): Vardenafil 5 mg Oral Tablet (Atom ID: 1543052)

fosphenytoin will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. fostamatinibfostamatinib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors fostamatinib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors fostemsavirvardenafil and fostemsavir both increase QTc interval. QTc prolongation reported with higher than recommended doses of fostemsavir. itraconazoleitraconazole will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Disclosure statement

vardenafil and fostemsavir both increase QTc interval. gemifloxacingemifloxacin and vardenafil both increase QTc interval. gemifloxacin and vardenafil both increase QTc interval. gepirone and vardenafil both increase QTc interval. gepotidacingepotidacin increases levels of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Which drugs interact with vardenafil?

If possible, avoid with sensitive substrates that are are extensively metabolized by CYP3A4 and have a narrow therapeutic index. If unable to avoid, monitor or modify substrate dose according to its prescribing information. gepotidacin increases levels of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. gilteritinib and vardenafil both increase QTc interval. granisetrongranisetron and vardenafil both increase QTc interval.

What are the most common side effects of vardenafil?

granisetron and vardenafil both increase QTc interval. grapefruitgrapefruit will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. grapefruit will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. griseofulvingriseofulvin will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. griseofulvin will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. itraconazole will increase the level or effect

• Vardenafil 5 mg offers a discreet treatment for erectile issues.
• Its onset of action is approximately 30 minutes after ingestion.
• It should be taken about an hour before intimacy.
• Do not crush or break the tablets; swallow whole.
• Patients should discuss health conditions with their doctor first.
• Vardenafil 5 mg is not a cure but manages symptoms.
• Regular use can improve confidence in sexual activity.
• Use caution if you have heart problems or low blood pressure.
• The medication should not be used by women.
• Safety during activities requiring alertness should be assessed.
• Overdose symptoms may include dizziness or chest pain.
• Always adhere to medical advice when using Vardenafil.

of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Usual Geriatric Dose for Erectile Dysfunction

escitalopram increases toxicity of vardenafil by QTc interval. eslicarbazepine acetate will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Transient decrease in heart rate and AV conduction delays may occur when initiating etrasimod. Owing to potential of additive effect on heart rate, etrasimod may increase risk of QT prolongation and Torsades de Pointes when coadministered with Class Ia or Class III antiarrhythmic drugs, or other drugs that prolong the QT interval. etravirineetravirine will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Mechanism of Action

etravirine will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. fedratinibfedratinib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors fedratinib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors fexinidazolefexinidazole will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors fexinidazole will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Patient resources

Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors fingolimodfingolimod and vardenafil both increase QTc interval. fingolimod and vardenafil both increase QTc interval. fluconazolefluconazole will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors fluconazole will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors fludrocortisonefludrocortisone will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. ivacaftorivacaftor will increase the level or effect

of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

What happens if I overdose?

Drugs that are known to prolong the QTc interval may have an increased the risk of ventricular arrhythmias. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors isavuconazonium sulfate will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors isoniazidisoniazid will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors isoniazid will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors istradefyllineistradefylline will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.